AVDL - Avadel Pharmaceuticals plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$21.43
DETAILS
HIGH:
$30.00
LOW:
$18.50
MEDIAN:
$20.00
CONSENSUS:
$21.43
DOWNSIDE:
0.97%
About Avadel Pharmaceuticals plc (https://www.avadel.com)
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Gregory J. Divis Jr. | Chief Executive Officer & Director | 1967 | $677,400 USD |
| Jerad G. Seurer | General Counsel, Company Secretary & Compliance Officer | 1974 | $634,700 USD |
| Thomas S. McHugh | Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer | 1965 | $530,119 USD |
| Angie Woods | Vice President of People & Culture | – | – |
| Gregory J. Davis | Vice President of Corporate and Business Development | 1965 | – |
| Jason Vaughn | Senior Vice President of Technical Operations | – | – |
| Jennifer Gudeman | Senior Vice President of Medical & Clinical Affairs | – | – |
| Marla Scarola | Senior Vice President of Regulatory & Quality | – | – |
| Polly A. Murphy | Chief Business Officer | 1965 | – |
| Susan Rodriguez | Chief Operating Officer | 1965 | – |